ripekg:evaluation/RIPEA4875E56C8C5C4ACF |
prov:used |
ripekg:study-design-evidence/RIPEA4875E56C8C5C4ACF |
ripekg:study-design-evidence/RIPEA4875E56C8C5C4ACF |
rdf:type |
rdfs:Resource |
ripekg:study-design-evidence/RIPEA4875E56C8C5C4ACF |
rdf:type |
owl:Thing |
ripekg:study-design-evidence/RIPEA4875E56C8C5C4ACF |
rdf:type |
ripe:IntegrityAssessmentEvidenceIntegrity assessment evidence |
ripekg:study-design-evidence/RIPEA4875E56C8C5C4ACF |
rdf:type |
ripe:StudyDesignEvidenceStudy design evidence |
ripekg:study-design-evidence/RIPEA4875E56C8C5C4ACF |
rdf:type |
tido:Evidence |
ripekg:study-design-evidence/RIPEA4875E56C8C5C4ACF |
prov:wasGeneratedBy |
ripekg:evidence-aggregation/RIPEA4875E56C8C5C4ACF |
ripekg:study-design-evidence/RIPEA4875E56C8C5C4ACF |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA4875E56C8C5C4ACF |
ripekg:study-design-evidence/RIPEA4875E56C8C5C4ACF |
ripe:concerns |
ripekg:work/10.1136%2Fannrheumdis-2014-205698Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial |
ripekg:study-design-evidence/RIPEA4875E56C8C5C4ACF |
ripe:recruitmentEndDateExtractionRationale |
No recruitment end date found after a full search of the document. |
ripekg:study-design-evidence/RIPEA4875E56C8C5C4ACF |
ripe:recruitmentStartDateExtractionRationale |
No recruitment start date found after a full search of the document. |
ripekg:study-design-evidence/RIPEA4875E56C8C5C4ACF |
ripe:studyEndDateExtractionRationale |
No study end date found after a full search of the document. |
ripekg:study-design-evidence/RIPEA4875E56C8C5C4ACF |
tido:supports |
ripekg:integrity-assessment-hypothesis/RIPEA4875E56C8C5C4ACF-human-2-2 |
ripekg:study-design-evidence/RIPEA4875E56C8C5C4ACF |
tido:supports |
ripekg:integrity-assessment-hypothesis/RIPEA4875E56C8C5C4ACF-inspectai-2-2 |